Xu Dong, Lu Qinghua, Hu Xun
Cancer Institute, The Second Affiliated Hospital, The Medical School, Zhejiang University, 88 Jiefang Road, Hangzhou, Zhejiang Province 310009, People's Republic of China.
Cancer Lett. 2006 Nov 18;243(2):274-80. doi: 10.1016/j.canlet.2005.11.031. Epub 2006 Jan 10.
P-glycoprotein accounts for the most intrinsic and acquired cancer multidrug resistance. To inhibit the expression of P-glycoprotein is one of the effective ways to reverse cancer drug resistance. Honokiol, a naturally occurring compound, has been demonstrated to combat cancer through mechanisms including inhibition of angiogenesis and induction of apoptosis. Here, we show that honokiol down-regulated the expression of P-glycoprotein at mRNA and protein levels in MCF-7/ADR, a human breast MDR cancer cell line. The down-regulation of P-glycoprotein was accompanied with a partial recovery of the intracellular drug accumulation, and of the sensitivities toward adriamycin. This study reveals a novel function of honokiol as an anti-cancer agent.
P-糖蛋白是导致最主要的内在性和获得性癌症多药耐药的原因。抑制P-糖蛋白的表达是逆转癌症耐药性的有效方法之一。厚朴酚是一种天然存在的化合物,已被证明可通过抑制血管生成和诱导凋亡等机制对抗癌症。在此,我们表明厚朴酚在人乳腺癌多药耐药细胞系MCF-7/ADR中,在mRNA和蛋白质水平下调了P-糖蛋白的表达。P-糖蛋白的下调伴随着细胞内药物蓄积以及对阿霉素敏感性的部分恢复。本研究揭示了厚朴酚作为抗癌剂的一种新功能。